Zimbabwe has turned down a significant American healthcare agreement valued at $367m (272 million pounds) over five years due to the United States' demand for confidential biological samples.
The decision came to light after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government representative later stated that the United States was requesting health data for research and commercial purposes while was not willing to guarantee the benefits from future vaccines.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further negotiations to secure a agreement agreeable to all parties so the country's vital HIV programme can be sustained.
Wider Background
This development comes after a comparable situation in Kenya, where a court halted a similar health funding agreement after legal challenges were raised about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and accountability.
According to reports, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no corresponding promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no assurance that the resulting innovations would be available to our citizens if a future disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting frameworks already established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a nation contributes its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent co-operation could be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but urged that talks should continue considering a large portion of the country's Aids initiatives were funded by international support.
"If technical issues exist, including those involving information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group added.
This impasse underscores the complex debate between receiving crucial international aid and protecting local interests in an increasingly data-driven world.